Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $102.9 million.

  • Krystal Biotech's Total Current Liabilities rose 92.85% to $102.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $102.9 million, marking a year-over-year increase of 92.85%. This contributed to the annual value of $102.9 million for FY2025, which is 92.85% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Total Current Liabilities is $102.9 million, which was up 92.85% from $91.3 million recorded in Q3 2025.
  • Over the past 5 years, Krystal Biotech's Total Current Liabilities peaked at $102.9 million during Q4 2025, and registered a low of $9.1 million during Q1 2021.
  • For the 5-year period, Krystal Biotech's Total Current Liabilities averaged around $51.6 million, with its median value being $35.4 million (2021).
  • Per our database at Business Quant, Krystal Biotech's Total Current Liabilities skyrocketed by 56094.71% in 2022 and then tumbled by 4196.27% in 2023.
  • Quarter analysis of 5 years shows Krystal Biotech's Total Current Liabilities stood at $25.7 million in 2021, then rose by 12.09% to $28.8 million in 2022, then rose by 14.72% to $33.1 million in 2023, then skyrocketed by 208.2% to $102.0 million in 2024, then rose by 0.93% to $102.9 million in 2025.
  • Its last three reported values are $102.9 million in Q4 2025, $91.3 million for Q3 2025, and $86.9 million during Q2 2025.